Teacher Retirement System of Texas Trims Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Teacher Retirement System of Texas trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 90.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,753 shares of the medical research company’s stock after selling 101,572 shares during the period. Teacher Retirement System of Texas’ holdings in IQVIA were worth $2,113,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Synergy Asset Management LLC bought a new position in IQVIA during the 4th quarter valued at $33,000. Versant Capital Management Inc lifted its position in shares of IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after purchasing an additional 93 shares during the last quarter. SBI Securities Co. Ltd. bought a new stake in IQVIA in the fourth quarter valued at about $60,000. UMB Bank n.a. raised its stake in IQVIA by 72.8% during the fourth quarter. UMB Bank n.a. now owns 401 shares of the medical research company’s stock valued at $79,000 after buying an additional 169 shares in the last quarter. Finally, Independence Bank of Kentucky grew its position in shares of IQVIA by 83.7% in the 4th quarter. Independence Bank of Kentucky now owns 406 shares of the medical research company’s stock worth $80,000 after acquiring an additional 185 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Performance

IQV opened at $179.91 on Thursday. The business has a 50 day moving average price of $193.92 and a two-hundred day moving average price of $207.10. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market capitalization of $31.72 billion, a price-to-earnings ratio of 23.99, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 1-year low of $179.12 and a 1-year high of $253.84.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

IQV has been the topic of several research reports. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Truist Financial restated a “buy” rating and issued a $263.00 price target (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Morgan Stanley boosted their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Finally, Stifel Nicolaus dropped their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.